Skip to main content Accessibility help
×
Home

Multiple Pathologies are Common in Alzheimer Patients in Clinical Trials

  • B. W. Wang (a1), E. Lu (a1), I. R. A. Mackenzie (a2), M. Assaly (a1), C. Jacova (a1), P. E. Lee (a1), B. L. Beattie (a1) and G. Y. R. Hsiung (a1)...

Abstract

Objective:

To determine the frequency of multiple pathology [Alzheimer Disease (AD) plus Vascular Dementia and/or Dementia with Lewy Bodies] in patients enrolled in clinical trials of AD therapy, and to compare the cognitive and functional assessments between patients with pure AD and AD with multiple pathology.

Methods:

We conducted a retrospective analysis of patients with a clinical diagnosis of AD who were enrolled in AD therapy clinical trials and subsequently received an autopsy for confirmation of their diagnosis from 2000 to 2009. Performance on cognitive screening tests, namely Modified Mini Mental state (3MS) exam, Mini Mental state Exam (MMSE) and Functional Rating Scale (FRS) were compared between patients with pure AD and multiple pathology.

Results:

Autopsy reports were available for 16/47 (34%) of deceased patients. Of these 16 patients, 5 (31%) had pure AD pathology, 10 (63%) had AD with other pathology, and 1 (6%) had non-AD pathology. Compared to patients with pure AD, patients with AD mixed with other pathology had poorer baseline FRS in problem-solving (p<0.01) and community affairs (p<0.02).

Conclusion:

While the strict enrollment criteria for clinical trials identified the presence of AD pathology in the majority of cases (15/16), multiple pathology was more common than pure AD in our series of autopsied patients. Premortem biomarkers that can distinguish between pure AD and AD with multiple pathology will be beneficial in future clinical trials and dementia patient management.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Multiple Pathologies are Common in Alzheimer Patients in Clinical Trials
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Multiple Pathologies are Common in Alzheimer Patients in Clinical Trials
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Multiple Pathologies are Common in Alzheimer Patients in Clinical Trials
      Available formats
      ×

Copyright

Corresponding author

Division of Neurology, Room S162, 2211 Wesbrook Mall, University of British Columbia, Vancouver, British Columbia, V6T 2B5, Canada. Email: hsiung@mail.ubc.ca

References

Hide All
1.Schneider, JA, Arvanitakis, Z, Bang, W, et al.Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197204.
2.Kovacs, GG, Alafuzoff, I, Al-Sarraj, S, et al.Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord. 2008;26(4):34350.
3.Sonnen, JA, Santa Cruz, K, Hemmy, LS, et al.Ecology of the aging human brain. Arch Neurol. 2011;68(8):104956.
4.O’Brien, JT, Erkinjuntti, T, Reisberg, B, et al.Vascular cognitive impairment. Lancet Neurol. 2003;2(2):8998.
5.McKeith, I, Mintzer, J, Aarsland, D, et al.Dementia with Lewy bodies. Lancet Neurol. 2004;3(1):1928.
6.Dubois, B, Feldman, HH, Jacova, C, et al.Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9(11): 111827.
7.Holmes, C, Boche, D, Wilkinson, D, et al.Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372 (9634):21623.
8.Alafuzoff, I, Helisalmi, S, Heinonen, EH, et al.Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer’s disease. Eur J Clin Pharmacol. 2000;55(11-12):81519.
9.McKhann, G, Drachman, D, Folstein, M, et al.Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984; 34(7):93944.
10.Gelinas, I, Gauthier, L, McIntyre, M, et al.Development of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementia. Am J Occup Ther. 1999;53 (5):47181.
11.Lanctot, KL, Hsiung, GY, Feldman, HH, et al.Assessing the validity of deriving clinical dementia rating (CDR) global scores from independently-obtained functional rating scale (FRS) scores in vascular dementia with and without Alzheimer’s disease. Int J Geriatr Psychiatry. 2009;24(10):11746.
12.Feldman, H, Levy, AR, Hsiung, GY, et al.A Canadian Cohort study of Cognitive Impairment and Related Dementias (ACCORD): study methods and baseline results. Neuroepidemiology. 2003; 22:26574.
13.Woodward, M, Mackenzie, IRA, Hsiung, GY, et al.Multiple brain pathologies in dementia are common. Eur Geriatr Med. 2010;1: 25965.
14.Wisniewski, HM, Silverman, W.Diagnostic criteria for the neuropathological assessment of Alzheimer’s disease: current status and major issues. Neurobiol Aging. 1997;18(4 suppl): s4350.
15.Newell, KL, Hyman, BT, Growdon, JH, et al.Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Experimental Neurol. 1999;58(11):114755.
16.McKeith, IG, Fairbairn, AF, Bothwell, RA, et al.An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology. 1994;44(5):8727.
17.Munoz, DG.The pathological basis of multi-infarct dementia. Alzheimer Dis Assoc Disord. 1991;5(2):7790.
18.Jellinger, KA, Attems, J.Is there pure vascular dementia in old age? J Neurol Sci. 2010;299(1-2):1504.
19.Cairns, NJ, Taylor-Reinwald, L, Morris, JC.Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core Alzheimers Dement. 2010;6(3):2749.
20.Esiri, MM, Nagy, Z, Smith, MZ, et al.Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease Lancet. 1999;354(9182):91920.
21.Jellinger, KA, Attems, J.Prevalence and impact of cerebrovascular pathology in Alzheimer’s disease and parkinsonism Acta Neurol Scand. 2006;114(1):3846.
22.Reed, BR, Mungas, DM, Kramer, JH, et al.Profiles of neuropsychological impairment in autopsy-defined Alzheimer’s disease and cerebrovascular disease. Brain. 2007;130(Pt 3): 7319.
23.McGuinness, B, Barrett, SL, Craig, D, et al.Executive functioning in Alzheimer’s disease and vascular dementia. Int J Geriatr Psychiatry. 2010;25(6):5628.
24.Baillon, S, Muhommad, S, Marudkar, M, et al.Neuropsychological performance in Alzheimer’s disease and vascular dementia: comparisons in a memory clinic population. Int J Geriatr Psychiatry. 2003;18(7):6028.
25.Tartaglia, MC, Rosen, HJ, Miller, BL.Neuroimaging in dementia. Neurotherapeutics. 2011;8(1):8292.
26.Whitwell, JL, Jack, CR Jr., Neuroimaging in dementia. Neurol Clin. 2007;25(3):843, 57, viii.
27.ADVANCE Collaborative Group, Patel, A, MacMahon, S, et al.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24): 256072.
28.Ligthart, SA, Moll van Charante, EP, Van Gool, WA, et al.Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag. 2010; 7(6):77585.
29.Shepherd, J, Blauw, GJ, Murphy, MB, et al.Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002 Nov 23;360(9346): 162330.
30.Gorelick, P, Scuteri, A, Black, SE, et al.Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2011;42(9):2672713.
31.Vuorinen, M, solomon, A, Rovio, S, et al.Changes in vascular risk factors from midlife to late life and white matter lesions: a 20-year follow-up study. Dement Geriatr Cogn Disord. 2011;31(2): 11925.
32.Bombois, S, Maurage, CA, Gompel, M, et al.Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol. 2007;64(4):5837.

Multiple Pathologies are Common in Alzheimer Patients in Clinical Trials

  • B. W. Wang (a1), E. Lu (a1), I. R. A. Mackenzie (a2), M. Assaly (a1), C. Jacova (a1), P. E. Lee (a1), B. L. Beattie (a1) and G. Y. R. Hsiung (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed